ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
L-Borneol ameliorates renal fibrosis induced by unilateral ureteral obstruction in rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-Borneol (BO), a naturally occurring bicyclic monoterpene, was investigated for its antifibrotic efficacy in an experimental model of surgically induced renal fibrosis in rats. Renal fibrosis was induced by unilateral ureteral obstruction (UUO). BO was administered at doses of 50, 100, and 200 mg/kg for 14 days post-UUO surgery. On the 15th day, urine and blood samples were collected to determine the status of the renal function. The kidneys were isolated following euthanasia and processed for estimation of oxidative stress, histological alterations (hematoxylin and eosin staining), and collagen deposition (Masson's Trichome staining). The biological targets of BO were explored using network pharmacology analysis. BO treatment improved kidney function and attenuated fibrosis, as evidenced by reduced hydroxyproline (HYP) content and decreased extracellular matrix accumulation in the renal tissues. BO also mitigated the UUO-induced alterations in the oxidative stress markers including reduced glutathione (GSH), superoxide dismutase (SOD), catalase, lipid peroxidation (LPO), and nitric oxide (NO). The effects of 50 and 100 mg/kg dose of BO were dose dependent, with the 100 mg/kg dose providing better renoprotection and reduced fibrosis. However, the 200 mg/kg dose appeared to induce alterations in kidney function. Gene and pathway analysis indicated that BO exerts its effects through interleukin-17 (IL-17), nuclear factor κB (NF-κB), phosphoinositide 3-kinase/protein kinase B (PI3K-Akt), tumor necrosis factor (TNF), AMP-activated protein kinase (AMPK), mitogen-activated protein kinase (MAPK), and vascular endothelial growth factor (VEGF) signaling pathways, with NFKB1 and MAPK8 identified as central hub genes. BO may represent a promising therapeutic candidate for RF associated with chronic kidney disease (CKD). Nevertheless, the potential toxicities observed with higher doses warrant further investigation into the underlying molecular mechanisms and clinical efficacy.
Indexed as
Identifiers
41329215What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.